Investor Relations

Latest Financial Results

Q1 2019

Quarter Ended Mar 31, 2019

Latest Annual Filing

Fiscal Year Ended Dec 31, 2018

View Filing

Stock Information

Company Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing innovative therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Shareholder Letter

Shareholder Letter

Download Shareholder Letter

Investor Contact Information

Company

Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road
Suite 455
Rockville, MD 20850

Investor Relations

ir@rexahn.com

Transfer Agent

Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Parkway
Atlantic Highlands, NJ 07716
T: 732-872-2727